SCHEMBL3383133

SCHEMBL3383133

CONC(=O)CCCCCCC(=O)c1ccc2ccccc2c1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 13/20 0.71
HDAC8 Q9BY41 12/20 0.71
HDAC3 O15379 6/20 0.64
HDAC4 P56524 6/20 0.64
HDAC7 Q8WUI4 6/20 0.64
HDAC2 Q92769 6/20 0.64
HDAC10 Q969S8 6/20 0.64
HDAC11 Q96DB2 6/20 0.64
HDAC6 Q9UBN7 6/20 0.64
HDAC9 Q9UKV0 6/20 0.64
HDAC5 Q9UQL6 6/20 0.64
SMN1; SMN2 Q16637 2/20 0.55
KDM4E B2RXH2 1/20 0.55
HPGD P15428 1/20 0.55
NPC1 O15118 1/20 0.52
ALDH1A1 P00352 1/20 0.52
RAB9A P51151 1/20 0.52
PTPN1 P18031 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1520961 0.83 HDAC1 (1.00) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL7230782 0.83 HDAC1 (0.65) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL3379588 0.83 HDAC1 (1.00) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL1520854 0.81 HDAC1 (0.97) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL26228944 0.80 HDAC1 (0.61) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL12952426 0.80 HDAC1 (0.68) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL4953757 0.80 HDAC1 (0.68) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL3379592 0.78 HDAC1 (0.70) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL7387271 0.78 HDAC1 (0.70) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL3381304 0.78 HDAC1 (0.70) HDAC1HDAC8HDAC3HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1280764-B1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2010-11-24 EP disclosed
US-20090181971-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. 2009-07-16 US disclosed
US-7288567-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2007-10-30 US disclosed
EP-1524262-A1 Inhibitors of histone deacetylase Methylgene, Inc. (CA) 2005-04-20 EP disclosed
US-20020115826-A1 Inhibitors of histone deacetylase 92229129 QUEBEC INC. (CA) 2002-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115826-A1 Inhibitors of histone deacetylase HDAC1, HDAC5, HDAC3 HDAC1 1/4885HDAC8 9/4885HDAC3 3/4885
US-20090181971-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 HDAC1 1/4885HDAC8 9/4885HDAC3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.